Navigation Links
Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
Date:11/11/2008

HAYWARD, Calif., Nov. 11 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead product, varespladib (A-002) at the American Heart Association (AHA) Annual Conference in New Orleans, Louisiana. Anthera has completed two Phase II trials in varespladib for the treatment of coronary heart disease. At the AHA conference, Anthera and its collaborators released new data from the Phase II PLASMA-2 study, which examined varespladib (A-002) in patients with cardiovascular disease.

Results from the most recent study showed that in patients with coronary heart disease (CHD) currently on statin therapy:

-- Varespladib had a significant anti-inflammatory effect as measured by a greater than 20% relative reduction in C-reactive protein

-- Varespladib had a substantial reduction in the target enzyme and pro- inflammatory marker, secretory phospholipase A2 (84%, p<.0001)

-- Varespladib resulted in a significant reduction in LDL in CHD patients (15%, p=.0006)

-- Varespladib caused a significant reduction in small LDL particles in CHD patients

-- Varespladib established a once a day dosing schedule with a clearly defined dose response

-- Varespladib continued to have a strong safety profile, confirming results from previous studies

"We are pleased to confirm the anti-inflammatory effect and safety profile of varespladib in patients with CHD," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with an opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"Along with the Phase II PLASMA data presented at the American College of Cardiology earlier this year, today's data at AHA confirms our confidence in varespladib and its potential as new therapeutic to treat cardiovascular disease," said Dr. Colin Hislop, M.D., Senior Vice President of Cardiovascular Products at Anthera Pharmaceuticals, Inc. "We look forward to data from the on-going FRANCIS trial to provide us with additional information on varespladib in the setting of an acute coronary event, specifically the impact of varespladib on markers of inflammation that may play a critical role in this disease."

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge

(650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Presents Data on Varespladib at ATVB Meeting
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
4. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
5. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
8. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
9. Job-related stress: NIST demonstrates fatigue effects in silicon
10. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
11. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):